Cellular Interferon Gamma and Granzyme B Responses to Cytomegalovirus-pp65 and Influenza N1 Are Positively Associated in Elderly

Viral Immunology

Volumn 29, Issue 3, 2016, Pages 169-175

  Theeten, Heidi ^a   Mathei, Catharina ^b   Peeters, Kelly ^a   Ogunjimi, Benson ^a,c   Goossens, Herman ^a   Ieven, Margareta ^a   Van Damme, Pierre ^a   Cools, Nathalie ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c HASSELT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOMEGALOVIRUS ANTIGEN PP65; GAMMA INTERFERON; GRANZYME B; IMMUNOGLOBULIN G; INFLUENZA VACCINE; CYTOMEGALOVIRUS MATRIX PROTEIN 65KDA; GRANZYME; GZMB PROTEIN, HUMAN; MATRIX PROTEIN; NA PROTEIN, INFLUENZA A VIRUS; PHOSPHOPROTEIN; SIALIDASE; VIRAL PROTEIN; VIRUS ANTIBODY; VIRUS ANTIGEN;

ADAPTIVE IMMUNITY; AGED; ARTICLE; CELLULAR IMMUNITY; COMMUNITY LIVING; FEMALE; GERIATRIC PATIENT; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNE STATUS; IMMUNOSENESCENCE; INFLUENZA A (H1N1); INFLUENZA A VIRUS (H1N1); INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; VIRUS IMMUNITY; AGING; BLOOD; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; IMMUNOLOGY; INFLUENZA; MORTALITY; VACCINATION; VIROLOGY;

AGED; AGING; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GRANZYMES; HUMANS; IMMUNITY, CELLULAR; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; INTERFERON-GAMMA; MALE; NEURAMINIDASE; PHOSPHOPROTEINS; VACCINATION; VIRAL MATRIX PROTEINS; VIRAL PROTEINS;

EID: 84964336295     PISSN: 08828245     EISSN: 15578976     Source Type: Journal    
DOI: 10.1089/vim.2015.0071     Document Type: Article

References (47)

1. Adriaensen W, Derhovanessian E, Vaes B, et al. CD4:8 Ratio >5 Is Associated With a Dominant Naive T-Cell Phenotype and Impaired Physical Functioning in CMV-Seropositive Very Elderly People: results From the BELFRAIL Study. J Gerontol A Biol Sci Med Sci 2014;70:11.
2. Cannon MJ, Schmid DS, and Hyde TB. Review of cyto-megalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol 2010;20: 202-213.
3. Chidrawar S, Khan N, Wei W, et al. Cytomegalovirus-seropositivity has a profound influence on the magnitude of major lymphoid subsets within healthy individuals. Clin Exp Immunol 2009;155:423-432.
4. Co MD, Orphin L, Cruz J, et al. In vitro evidence that commercial influenza vaccines are not similar in their ability to activate human T cell responses. Vaccine 2009;27:319-327.
5. Crough T, and Khanna R. Immunobiology of human cy-tomegalovirus: from bench to bedside. Clin Microbiol Rev 2009;22:22.
6. Della Cioppa G, Nicolay U, Lindert K, et al. Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59 ((R)) adjuvant: results from a dose-finding clinical trial in older adults. Hum Vaccines Im-munotherapeutics 2012;8:216-227.
7. den Elzen WP, Vossen AC, Cools HJ, et al. Cytomegalo-virus infection and responsiveness to influenza vaccination in elderly residents of long-term care facilities. Vaccine 2011;29:4869-4874.
8. Deng Y, Jing Y, Campbell AE, et al. Age-related impaired type 1 T cell responses to influenza: reduced activation ex vivo, decreased expansion in CTL culture in vitro, and blunted response to influenza vaccination in vivo in the elderly. J Immunol 2004;172:3437-3446.
9. Derhovanessian E, Maier AB, Hahnel K, et al. Latent infection with cytomegalovirus is associated with poor memory CD4 responses to influenza a core proteins in the elderly. J Immunol 2014;193:3624-3631.
10. Derhovanessian E, Theeten H, Hahnel K, et al. Cytomegalovirus-associated accumulation of late-differentiated CD4 T-cells correlates with poor humoral response to influenza vaccination. Vaccine 2013;31:685-690.
11. Forrest BD, Pride MW, Dunning AJ, et al. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol 2008;15:1042-1053.
12. Furman D, Jojic V, Sharma S, et al. Cytomegalovirus infection enhances the immune response to influenza. Sci Transl Med 2015;7:281ra243.
13. Haq K, and McElhaney JE. Immunosenescence: influenza vaccination and the elderly. Curr Opin Immunol 2014;29: 38-42.
14. Hoft DF, Babusis E, Worku S, et al. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J Infect Dis 2011;204:845-853.
15. Hsu JP, Phoon MC, Koh GC, et al. Comparison of neutralizing antibody and cell-mediated immune responses to pandemic H1N1 2009 influenza virus before and after H1N1 2009 influenza vaccination of elderly subjects and healthcare workers. Int J Infect Dis 2012;16:e621-e627.
16. Janetzki S, Panageas K, Ben-Porat L, et al. Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Im-munother 2008;57:12.
17. Kern F, Faulhaber N, Frommel C, et al. Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides. Eur J Immunol 2000;30:1676-1682.
18. Klages S, Ruger B, and Jahn G. Multiplicity dependent expression of the predominant phosphoprotein pp65 of human cytomegalovirus. Virus Res 1989;12:159-168.
19. Loeth N, Assing K, Madsen HO, et al. Humoral and cellular CMV responses in healthy donors; identification of a frequent population of CMV-specific, CD4+ T cells in se-ronegative donors. PloS One 2012;7:e31420.
20. Lopo S, Vinagre E, Palminha P, et al. Seroprevalence to cytomegalovirus in the Portuguese population, 2002-2003. Euro Surveill 2011;16.
21. McElhaney JE, Ewen C, Zhou X, et al. Granzyme B: correlates with protection and enhanced CTL response to influenza vaccination in older adults. Vaccine 2009;27: 2418-2425.
22. McElhaney JE, Xie D, Hager WD, et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol 2006;176:7.
23. Moodie Z, Price L, Janetzki S, et al. Response determination criteria for ELISPOT: toward a standard that can be applied across laboratories. Methods Mol Biol 2012; 792:11.
24. Moro-Garcia MA, Alonso-Arias R, Lopez-Vazquez A, et al. Relationship between functional ability in older people, immune system status, and intensity of response to CMV. Age 2012;34:17.
25. Nowacki TM, Kuerten S, Zhang W, et al. Granzyme B production distinguishes recently activated CD8(+) memory cells from resting memory cells. Cell Immunol 2007;247:36-48.
26. O'Connor D, Truck J, Lazarus R, et al. The effect of chronic cytomegalovirus infection on pneumococcal vaccine responses. J Infect Dis 2014;209:1635-1641.
27. Ogunjimi B, Smits E, Heynderickx S, et al. Influence of frequent infectious exposures on general and varicellazoster virus-specific immune responses in pediatricians. Clin Vaccine Immunol 2014;21:417-426.
28. Ogunjimi B, Theeten H, Hens N, et al. Serology indicates cytomegalovirus infection is associated with varicella-zoster virus reactivation. J Med Virol 2014;86:812-819.
29. Pawelec G. Hallmarks of human "immunosenescence": adaptation or dysregulation? Immun Ageing 2012;9:4.
30. Pera A, Campos C, Corona A, et al. CMV Latent Infection Improves CD8+T Response to SEB Due to Expansion of Polyfunctional CD57+Cells in Young Individuals. PloS One 2014;9:e88538.
31. Quiroga JA, Llorente S, Castillo I, et al. Cellular immune responses associated with occult hepatitis C virus infection of the liver. J Virol 2006;80:10972-10979.
32. Roman F, Clement F, Dewe W, et al. Effect on cellular and humoral immune responses of the AS03 adjuvant system in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials. Clin Vaccine Immunol 2011;18:835-843.
33. Salk HM, Haralambieva IH, Ovsyannikova IG, et al. Granzyme B ELISPOT assay to measure influenza-specific cellular immunity. J Immunol Methods 2013;398:44-50.
34. Sansoni P, Vescovini R, Fagnoni FF, et al. New advances in CMV and immunosenescence. Exp Gerontol 2014;55: 54-62.
35. Saurwein-Teissl M, Lung TL, Marx F, et al. Lack of antibody production following immunization in old age: association with CD8(+)CD28(-) T cell clonal expansions and an imbalance in the production of Th1 and Th2 cytokines. J Immunol 2002;168:5893-5899.
36. Skowronski DM, Hottes TS, McElhaney JE, et al. Immuno-epidemiologic correlates of pandemic H1N1 surveillance observations: higher antibody and lower cell-mediated immune responses with advanced age. J Infect Dis 2011;203: 158-167.
37. Sridhar S, Begom S, Bermingham A, et al. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat Med 2013;19:1305-1312.
38. Terrazzini N, Bajwa M, Vita S, et al. Cytomegalovirus infection modulates the phenotype and functional profile of the T-cell immune response to mycobacterial antigens in older life. Exp Gerontol 2014;54:94-100.
39. Trzonkowski P, Mysliwska J, Szmit E, et al. Association between cytomegalovirus infection, enhanced proin-flammatory response and low level of anti-hemagglutinins during the anti-influenza vaccination-an impact of im-munosenescence. Vaccine 2003;21:3826-3836.
40. Varga M, Gorog D, Kari D, et al. Cytomegalovirus ser-oprevalence among solid organ donors in Hungary: correlations with age, gender, and blood group. Transplant Proc 2011;43:1233-1235.
41. Wald A, Selke S, Magaret A, et al. Impact of human cytomegalovirus (CMV) infection on immune response to pandemic 2009 H1N1 influenza vaccine in healthy adults. J Med Virol 2013;85:1557-1560.
42. Waller EC, Day E, Sissons JG, et al. Dynamics of T cell memory in human cytomegalovirus infection. Med Microbiol Immunol 2008;197:83-96.
43. Wilkinson TM, Li CK, Chui CS, et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med 2012;18:274-280.
44. Wills MR, Carmichael AJ, Mynard K, et al. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol 1996;70:7569-7579.
45. World-Health-oganisation Vaccination coverage data as reported to the World Health Organisation. Available at: http://data.euro.who.int/cisid/?TabID=87406 (accessed May 2006).
46. World-Health-Organization Seasonal Influenza, Fact sheet N°211. Available at: www.who.int/mediacentre/factsheets/fs211/en/(accessed February 2015).
47. World-Health-Organization. Influenza vaccines, WHO position paper-November 2012.WER 2012; 7:461-476.